Find a Speaker Event
or

Results

In-person events

Wednesday, May 28, 2025
6:00 PM CST

Out-of-Office Live

Speaker:

Ravi Chauhan, MD

Location:

Folks Folly, 551 S Mendenhall Rd., Memphis, TN 38117

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Tuesday, June 10, 2025
6:00 PM EST

Out-of-Office Live

Speaker:

Ravi Chauhan, MD

Location:

Meat Market Boca Raton Steakhouse, 2000 NW 19th Street, Boca Raton, FL 33431

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Wednesday, June 11, 2025
6:30 PM PST

Out-of-Office Live

Speaker:

Chinedu Mmeje, MD, FACS

Location:

The Henry Phoenix, 4455 E. Camelback Rd, Phoenix, AZ 85018

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Tuesday, June 17, 2025
6:30 PM EST

Out-of-Office Live

Speaker:

Patrick J. Hensley, MD

Location:

Jeff Ruby's Steakhouse, 101 W Vine Street, Lexington, KY 40507

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Wednesday, June 18, 2025
6:15 PM EST

Out-of-Office Live

Speaker:

Gautam Jayram, MD

Location:

The Capital Grille, 94 Perimeter Center W, Dunwoody, GA 30346

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Wednesday, June 18, 2025
6:30 PM EST

Out-of-Office Live

Speaker:

Katie Murray, DO, MS, FACS

Location:

Artisan, 1 Memorial Road, West Hartford, CT 06107

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Thursday, June 19, 2025
12:00 PM MST

In-Office Live

Speaker:

Chad Reichard, MD

Location:

Idaho Urologic Institute, 2855 E Magic View Dr., Meridian, ID 83642

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Thursday, June 26, 2025
6:00 PM EST

Out-of-Office Live

Speaker:

Aaron Berger, MD

Location:

Baker Street Steakhouse, 4820 N Clinton Street, Fort Wayne, IN 46825

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Thursday, July 24, 2025
6:00 PM CST

Out-of-Office Live

Speaker:

Ravi Chauhan, MD

Location:

Ruth's Chris Steak House, 17840 Dallas Parkway, Dallas, TX 75287

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Saturday, August 2, 2025
9:15 AM PST

Out-of-Office Live

Speaker:

Lawrence Karsh, MD, FACS, CPI

Location:

Hilton Phoenix at the Peak, 7677 N 16th St., Phoenix, AZ 85020

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Online events

Friday, May 23, 2025
12:30 PM EST

Hybrid (Speaker Remote)

Speaker:

Gautam Jayram, MD

Location:

AtlantiCare Group Physician Urology, 2110 New Road First Floor, Linwood, NJ 08221

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Tuesday, June 3, 2025
5:30 PM EST

Virtual (Fully Remote)

Speaker:

Gautam Jayram, MD

Location:

Garden State Urology, 16 Eden Ln, Whippany, NJ 07981

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

Thursday, June 12, 2025
7:00 PM EST

Virtual (Fully Remote)

Speaker:

Katie Murray, DO, MS, FACS

Location:

Online

Description:

Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.

INDICATION AND IMPORTANT SAFETY INFORMATION
ADSTILADRIN® (nadofaragene firadenovec-vncg) suspension, for intravesical use
INDICATION FOR USE
  • ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS:
  • ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.

WARNINGS AND PRECAUTIONS
  • Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.

  • Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.

DOSAGE AND ADMINISTRATION:
  • Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.

USE IN SPECIFIC POPULATIONS:
  • Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.

ADVERSE REACTIONS:
  • The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch, or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING.

Please see full Prescribing Information.